CA-PONY.AI
Pony.ai, a leading global autonomous mobility company, held a Memorandum of Understanding (MoU) signing ceremony today with the Government of the Grand Duchy of Luxembourg (“The Government”) to advance the development of autonomous mobility in Luxembourg. The MoU was signed by Pony.ai Co-Founder and CEO Dr. James Peng and Luxembourg’s Minister of the Economy Lex Delles. This MoU represents a collaborative partnership between Luxembourg and Pony.ai, with the objective of fostering the research, development, and deployment of autonomous vehicles in Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306928526/en/
Delegation from the Government of the Grand Duchy of Luxembourg visits Pony.ai’s office in Fremont, California, March 6, 2024 (Photo: Business Wire)
As a global leader in innovation and technology, Luxembourg presents an excellent opportunity for Pony.ai to further develop its leading autonomous mobility technology in Europe. Pony.ai, with the support of Luxinnovation and local stakeholders, intends to set up a regional hub in Luxembourg, which will serve as a center for Pony.ai’s cutting-edge research and development of autonomous vehicle technology. Pony.ai’s Luxembourg-based hub will be pivotal in driving technological advancements and tailoring solutions for the European market. In addition, the Government and Pony.ai aim to develop a robust local network to support operational capabilities in Luxembourg. Pony.ai looks forward to building strong local partnerships to support this effort.
Pony.ai co-founder and CEO Dr. James Peng said: “As a leading global autonomous vehicle company, Pony.ai is delighted to partner with Luxembourg as we continue our global expansion. We aim to bring to this partnership our cutting-edge AV technology, comprehensive training programs, and a commitment to establish a regional hub in Luxembourg as we continue our global expansion.”
Luxembourg Minister of the Economy Lex Delles said: “The intelligent mobility sector is one of our priorities with regard to the diversification of Luxembourg’s economy. Our aim is to make the Grand Duchy a pioneer in the field of autonomous driving on a European scale. As such, I am very pleased with the signature of an MoU with Pony.ai, a leader in autonomous mobility technologies and services. The signature today formalizes our collaboration and is an important step towards creating a synergy between the technical expertise of Pony.ai and the Luxembourg government's political strategy. The latter aims to promote research and technological development, job creation and sustainable economic growth.”
Pony.ai is a leader in autonomous mobility and in the commercialization of autonomous driving, operating Robotaxi, Robotruck and Personally Owned Vehicle (POV) business units, developing the safest autonomous driving capabilities on a global scale. Pony.ai is excited to continue its expansion into Luxembourg and the European market. For the past year, Pony.ai has engaged in detailed conversations surrounding robotaxi deployment use cases and opportunities with local stakeholders in Luxembourg and believes the country is an exciting and innovative region to introduce Pony.ai’s leading autonomous vehicles.
About Pony.ai
Leading global autonomous driving company Pony.ai, Inc. (“Pony.ai”) is pursuing an ambitious vision for autonomous mobility. We aim to bring safe, sustainable, and accessible mobility to the entire world. We believe that autonomous technology can make our roads exponentially safer for travelers. Founded in late 2016, Pony.ai has been a pioneer in extending autonomous mobility technologies and services at a rapidly expanding footprint of sites around the world. Pony.ai has formed partnerships with leading OEMs, including Toyota, SAIC, SANY, FAW Group, GAC Group, etc. To date, Pony.ai has driven over 30 million autonomous testing and operation kilometers (over 18.6 million miles) on open roads worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306928526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom